Olga Lomovskaya
Profile
Olga Lomovskaya was the founder of Rempex Pharmaceuticals, Inc. founded in 2011, where she held the title of Vice President-Biology.
She also held the position of Associate Director-Biology at Essential Therapeutics, Inc. and Vice President-Biology at MPEX Pharmaceuticals, Inc. Dr. Lomovskaya has a graduate degree from Moscow State University and a doctorate from the Russian Academy of Sciences.
Former positions of Olga Lomovskaya
| Companies | Position | End |
|---|---|---|
Essential Therapeutics, Inc.
 Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Corporate Officer/Principal | - |
Rempex Pharmaceuticals, Inc.
 Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Founder | - |
MPEX Pharmaceuticals, Inc.
 MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Training of Olga Lomovskaya
| Russian Academy of Sciences | Doctorate Degree |
Experiences
Positions held
Linked companies
| Private companies | 4 |
|---|---|
MPEX Pharmaceuticals, Inc.
MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Commercial Services |
| Moscow State University | Consumer Services |
Essential Therapeutics, Inc.
Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Health Technology |
Rempex Pharmaceuticals, Inc.
Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Olga Lomovskaya
